Centene CFO Says 2027 Growth Starts From $4.70 A Share, Not The Raised $5.20 Outlook
Drew Asher said 50 cents of 2026 earnings will not recur, yet Centene still expects 2027 growth from both baselines.
Centene Chief Financial Officer Drew Asher said on the company's third-quarter earnings call Tuesday that 2027 should be measured from about $4.70 of adjusted earnings per share, not the raised 2026 outlook of more than $5.20. Centene, a managed care company serving Medicaid, Medicare and Marketplace members, still expects to grow from both figures, he said.
Fifty cents that will not repeat
Asher said 2026 earnings include 50 cents that the company does not expect in 2027. He broke it into $180 million from Marketplace and $160 million from Medicare, largely the standalone prescription drug plan business. "Approximately $4.70 of adjusted EPS" is the appropriate jump-off point for 2027 tailwinds and headwinds, he said.
Still, he said Centene expects to grow adjusted EPS relative to both the $4.70 base and the revised 2026 guidance. CEO Sarah London made the same point, saying the company expects to grow earnings off both its updated baseline and its updated guidance.
The raised outlook follows third-quarter adjusted diluted EPS of 58 cents, ahead of the company's expectations. It lifts the 2026 view from prior guidance of more than $4.80, driven by Medicare strength led by the drug plan business, a Marketplace pre-tax margin at the top of its 4.5% to 5% range, and lower interest expense at a midpoint of $610 million.
Tailwinds and headwinds for 2027
Asher's selected tailwinds against the $4.70 base:
- Continued progress matching Medicaid rates to patient acuity, leaving a slight improvement in the Medicaid medical cost ratio.
- A better Marketplace pre-tax margin.
- Medicare Advantage moving from break-even in 2026 to better than break-even.
- Drug plan membership growth and higher premium yield, plus a lower overhead ratio.
The headwinds he named are Medicaid membership attrition from the federal OB-3 law and the removal of the unsatisfactory immigration status population from managed care in California. The drug plan's 2026 margin outperformance should also reset, at least initially, to a lower level; he said the opening expectation is probably 2% to 3%.
Medicaid ended the quarter with 11.9 million members, down 5% year to date, and the company still expects a full-year decline of 8% to 9%.
A CFO handoff and a February date
Asher said Chris Nezepor, the next CFO, has worked side by side with him and the finance team for the last couple of months. The company intends to give initial 2027 guidance on its fourth-quarter call in February.
London said more precision will come with visibility into Medicare and Marketplace open enrollment, January 1 Medicaid rates and the businesses' exit trajectory. Centene's total debt stands at $15.0 billion, down from $18.5 billion at the end of 2024, after another $1.1 billion of senior notes were repurchased since the second-quarter call.
Formal 2027 guidance arrives in early February, once open enrollment results and January 1 Medicaid rate decisions are in.
Sources
- Centene Medical Costs Run Higher Despite Upbeat Earnings View — news.bloomberglaw.com
- Centene (CNC) Q3 Earnings and Revenues Surpass Estimates — Yahoo Finance
- How Much Should This Move Change Your View Of Centene Stock? — Yahoo Finance
- Centene posts $71M loss, $50.6B in revenue for Q3 — fiercehealthcare.com
- Centene Reports Small Loss As CEO Says Health Insurer On Track For ‘Faster Recovery’ — Yahoo Finance
More on Centene
- Centene CEO Sees 'More Positive Signals Than Negative' On Medicaid As Work Requirements Phase In Slowly
- Centene's Medicare Star Ratings Slide: Only About 42% Of Members Sit In 3.5-Star Plans, Down From About 60%
- Centene Raises 2026 Adjusted Earnings Floor By $0.40 To Above $5.20 Despite A Third-Quarter Loss